Sumitomo Pharma America: Clinical Trials & Research Profile
Biopharma Industry (Global / Institutional) · Primary Focus: Oncology and Hematology
| Clinical Trial Metric | Verified Public Record |
|---|---|
| Organization Type | Consolidated Trial Sponsor |
| Institutional Sector & Location | Biopharma Industry (Global / Institutional) |
| Primary Therapeutic Area | Oncology and Hematology |
| Active Phase II & III Studies | 5 active (5 recruiting now) |
| Total Tracked Studies (2018 to 2026) | 15 (9 with California sites) |
| Completed vs Early-Stopped Studies | 3 completed / 7 stopped (46.7% stop rate) |
| Median Closed Enrollment | 50 participants |
| FDA Drugs@FDA Original Approvals | 0 all-time (0 from 2018 to 2026) |
| Physical Hospital Site Disclosure | 99.8% named hospital slots |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.
Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI -> · AI for Healthcare · Healthcare Price & Patent Cliff Crosswalk